Nanosonics Limited (NNCSF) Financier

Nanosonics Ltd. engages in the provision of research, development, and commercialization of infection control and decontamination products and related technologies. The company is headquartered in Sydney, New South Wales and currently employs 470 full-time employees. The company went IPO on 2007-05-17. The firm's principal activities include the manufacturing and distribution of the trophon ultrasound probe disinfector and its associated consumables and accessories. The company is focused on the research, development, and commercialization of infection control and decontamination products and related technologies. Trophon technology includes high-frequency ultrasonic vibrations that generate a sonically activated hydrogen peroxide (H2O2) mist that kills bacteria, fungi, and viruses. Its products include trophon2, Nanosonics Auditpro, and trophon EPR. Its trophon2 includes AcuTrace radio frequency identification (RFID) technology, which enables digital record keeping and captures disinfection data. Nanosonics AuditPro is an automated digital system that combines clinician infection prevention decision making, with the Trophon 2 device infection control workflow data, and patient procedure information.